What can you say about bngo

Bionano Genomics (BNGO) presents a complex financial profile, characterized by:

1. Negative P/E Ratio: The -0.24 P/E ratio suggests the company is currently generating losses, which may raise concerns among investors.

2. Positive Revenue Growth: A 30.51% year-on-year revenue growth rate indicates a promising expansion in business operations.

3. Persistent Earnings Challenges: Despite revenue growth, BNGO faces significant challenges in generating positive earnings, as evidenced by the declining Basic EPS over recent quarters.

4. Market Capitalization: With a market cap of $56.88 million, BNGO remains a relatively small player in its sector.

5. Moderate P/S Ratio: The 1.56 P/S ratio suggests investors are currently valuing BNGO at a moderate level compared to its revenue.

6. Stock Performance: The recent 0.97% increase in stock price to $1.04 indicates some investor confidence, but the overall trend remains volatile.

In summary, BNGO's negative earnings contrast with its robust revenue growth, presenting an intriguing investment case requiring careful evaluation of its growth potential and financial health amidst persistent earnings challenges.